Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.

ABSTRACT:

Background

Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA). Low-pass whole-genome sequencing (lpWGS) of ctDNA can provide information on mCRPC behaviour.

Objective

To validate and clinically qualify plasma lpWGS for mCRPC.

Design, setting, and participants

Plasma lpWGS data were obtained for mCRPC patients consenting to optional substudies of two prospective phase 3 trials (FIRSTANA and PROSELICA). In FIRSTANA, chemotherapy-naïve patients were randomised to treatment with docetaxel (75 mg/m²) or cabazitaxel (20 or 25 mg/m²). In PROSELICA, patients previously t

SUBMITTER: Sumanasuriya S 

PROVIDER: S-EPMC8329366 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature